SCRI Development Innovations, LLC: all 179 studies

Page 2 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary SiteCompletedNCT00193609Phase 2Results posted
• Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary SiteCompletedNCT00193596Phase 3Results posted
• A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00193492Phase 2Results posted
• Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00193479Phase 2Results posted
• Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerCompletedNCT00193453Phase 2Results posted
• Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung CancerCompletedNCT00193427Phase 2Results posted
• Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00193414Phase 2Results posted
• Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerCompletedNCT00193375Phase 2Results posted
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedNCT00193258Phase 1/2Results posted
• Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerCompletedNCT00193219Phase 2Results posted
• Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193206Phase 2Results posted
• Docetaxel Plus Imatinib Mesylate in Metastatic Breast CancerCompletedNCT00193180Phase 2Results posted
• Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus CancerCompletedNCT00193128Phase 1/2Results posted
• Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast CancerCompletedNCT00193063Phase 2Results posted
• Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193050Phase 2Results posted
• Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast CancerCompletedNCT00193037Phase 2Results posted
• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Active, not recruitingNCT06773910Phase 2
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
• LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedNCT02649673Phase 1
• Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBCCompletedNCT02436772
• iCORE: Collaborative Orthopedics Outcomes RegistryWithdrawnNCT02422667
• INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
• Sarah Cannon Outcomes RegistryWithdrawnNCT02356822
• Study of Trametinib and Nab-paclitaxel in Patients With MelanomaWithdrawnNCT02300935Phase 1
• Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT02125084Phase 1
• Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With DocetaxelWithdrawnNCT02035124Phase 2
• Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
• Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or LongerCompletedNCT01522833
• Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid TumorsCompletedNCT01343498Phase 1
• A Retrospective Cohort Study of Infusion Reactions Due to VectibixCompletedNCT01156090
• A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host DiseaseWithdrawnNCT01028313Phase 2
• SCRI Tissue Testing RegistryTerminatedNCT00965861
• Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology SettingCompletedNCT00877045
• Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary CancerCompletedNCT00876408
• Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell CarcinomaCompletedNCT00876382
• Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast CancerCompletedNCT00876070
• PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid TumorsCompletedNCT00759928Phase 1
• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid TumorsCompletedNCT00613145Phase 1
• PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced MalignanciesCompletedNCT00611793Phase 1
• Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid TumorsCompletedNCT00611689Phase 1
• LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid TumorsCompletedNCT00556088Phase 1
• LBH589 and Gemcitabine in the Treatment of Solid TumorsTerminatedNCT00550199Phase 1
• Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesCompletedNCT00315861Phase 1
• Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerCompletedNCT00308529Phase 2
• Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00294931Phase 2
• Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerCompletedNCT00294190Phase 2
• Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
• Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid TumorsCompletedNCT00193583Phase 1
• Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid TumorsCompletedNCT00193570Phase 1
• Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
• Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2
• Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine CarcinomaCompletedNCT00193531Phase 2
• Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00193518Phase 2
• Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell LymphomaCompletedNCT00193505Phase 2
• Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00193466Phase 2
• Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaCompletedNCT00193440Phase 2
• Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerCompletedNCT00193401Phase 2
• Weekly Topotecan in the Second-Line Treatment of Small Cell Lung CancerCompletedNCT00193388Phase 2
• Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung CancerCompletedNCT00193362Phase 3
• Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung CancerCompletedNCT00193349Phase 2
• Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerCompletedNCT00193336Phase 2
• Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly PatientsCompletedNCT00193323Phase 2
• Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung CancerCompletedNCT00193310Phase 2
• Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00193297Phase 2
• Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck CancerCompletedNCT00193284Phase 2
• Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate CancerCompletedNCT00193271Phase 2
• Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung CancerCompletedNCT00193245Phase 2
• Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate CancerCompletedNCT00193232Phase 2
• Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate CarcinomaCompletedNCT00193193Phase 2
• Weekly Topotecan in Patients Treated for Metastatic Colorectal CancerCompletedNCT00193167Phase 2
• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00193154Phase 2
• Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal CancerCompletedNCT00193141Phase 2
• Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast CancerCompletedNCT00193115Phase 2
• Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast CancerTerminatedNCT00193102Phase 2
• Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast CancerCompletedNCT00193089Phase 2
• Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast CancerCompletedNCT00193076Phase 2
• Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast CancerTerminatedNCT00193024Phase 2
• Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast CancerCompletedNCT00193011Phase 3

← SCRI Development Innovations, LLC overview and focus areas